This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug
by Zacks Equity Research
Panbela (PBLA) surges as it enrolls the first patient in the mid-stage clinical study to evaluate CPP-1X-T (Eflornithine tablets) for treating recent-onset type 1 diabetes.
CRSPNegative Net Change KALAPositive Net Change ALLONo Net Change PBLANo Net Change
biotechnology medical
Biotech Stock Roundup: MRNA Provides Update, KALA, IFRX Surge on Regulatory News
by Zacks Equity Research
Regulatory and pipeline updates from Moderna (MRNA) and KALA are the key highlights for the biotech sector.
MRNANegative Net Change IFRXPositive Net Change KALAPositive Net Change
biotechnology pharmaceuticals
KALA Up on Fast Track Designation to Lead Ocular Candidate
by Zacks Equity Research
KALA gets Fast Track Designation from the FDA for lead candidate KPI-012 to treat persistent corneal epithelial defects.
NVOPositive Net Change LGNDPositive Net Change KALAPositive Net Change
biotechnology biotechs pharmaceuticals
Fusion (FUSN) to Begin Clinical Study on Targeted Alpha Therapy
by Zacks Equity Research
Fusion (FUSN) surges after investigational new drug application clearance by the FDA for its targeted alpha therapy FPI-2068, co-developed with AstraZeneca.
AZNNegative Net Change MRKPositive Net Change FUSNPositive Net Change ALLONo Net Change
biotechnology medical oncology-screening
MAIA Biotechnology (MAIA) Up on Positive Data From NSCLC Study
by Zacks Equity Research
MAIA Biotechnology (MAIA) gains on encouraging data on lead candidate from Part A of its mid-stage study in advanced non-small cell lung cancer.
REGNPositive Net Change NVOPositive Net Change LGNDPositive Net Change MAIANegative Net Change
biotechnology biotechs pharmaceuticals
Humacyte (HUMA) Completes Enrollment in HAV Technology Study
by Zacks Equity Research
Humacyte (HUMA) surges as it completes patient enrollment in a late-stage clinical study on the human acellular vessel product for vascular access in hemodialysis patients.
CRSPNegative Net Change KALAPositive Net Change ALLONo Net Change HUMANegative Net Change
biotechnology medical
Panbela (PBLA) Regains Flynpovi Rights to Treat FAP
by Zacks Equity Research
Panbela (PBLA) shares surge as it regains rights to develop and commercialize Flynpovi for the familial adenomatous polyposis treatment.
CRSPNegative Net Change KALAPositive Net Change ALLONo Net Change PBLANo Net Change
biotechnology medical
Exelixis (EXEL) Surges 25.4% so Far in 2023: Here's Why
by Zacks Equity Research
Exelixis' (EXEL) efforts to expand Cabometyx's label and develop additional drugs to expand its portfolio should reap rewards for the company.
BMYPositive Net Change NVOPositive Net Change EXELNegative Net Change LGNDPositive Net Change
biotechnology biotechs pharmaceuticals
Apellis (APLS) Stock Up 50% in Three Months: Here's Why?
by Zacks Equity Research
Apellis (APLS) stock rises 50% in the past three months owing to the approval of Syfovre (pegcetacoplan injection) in February. An encouraging uptake in its first marketed product, Empaveli, also contributed to the surge.
CRSPNegative Net Change KALAPositive Net Change APLSNegative Net Change ALLONo Net Change
biotechnology medical
Should You Buy Lululemon (LULU) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
LULUNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
New Strong Buy Stocks for April 11th
by Zacks Equity Research
AGESY, ACLX, MT, X and GBX have been added to the Zacks Rank #1 (Strong Buy) List on April 11, 2023.
MTPositive Net Change AGESYNegative Net Change GBXPositive Net Change ACLXNegative Net Change
biotechnology medical
Cytokinetics (CYTK) Dips 20% so Far in 2023 on Setbacks
by Zacks Equity Research
Cytokinetics (CYTK) declines 20% in the year so far as it suffers a regulatory setback for its NDA for omecamtiv mecarbil.
NVOPositive Net Change LGNDPositive Net Change CYTKNegative Net Change
biotechnology biotechs
Endeavour Silver (EXK) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
EXKPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
5 Diverse Medical Stocks to Buy for 2023 and Beyond
by Shaun Pruitt
The top and bottom-line growth make these Zacks Medical stocks very attractive.
NVOPositive Net Change HUMPositive Net Change CHGCYNegative Net Change HZNPPositive Net Change CSLLYNegative Net Change
biotechnology cancer cell-therapy dividend-investing dividends gene-therapy hmo hospitals immuno-therapy insurance large-cap medical pharmaceuticals vaccines
Immunic's (IMUX) Ulcerative Colitis Study Shows Positive Data
by Zacks Equity Research
Immunic (IMUX) reports positive results from the maintenance phase of the phase II study evaluating its lead candidate, vidofludimus calcium, to treat patients with ulcerative colitis.
CRSPNegative Net Change KALAPositive Net Change KODNo Net Change IMUXPositive Net Change
biotechnology immuno-therapy medical
Palisade (PALI) Enrolls First Patient in LB1148 Study in China
by Zacks Equity Research
Palisade's (PALI) development partner, Newsoara, enrolls first patient in the late-stage clinical study of LB1148 to improve postoperative GI function for patients in China.
CRSPNegative Net Change KALAPositive Net Change KODNo Net Change PALINegative Net Change
biotechnology medical
Prothena (PRTA) Gains 29% in One Year: Will the Momentum Continue?
by Zacks Equity Research
Prothena (PRTA) surges 29% in the past one year as investors are optimistic on its promising Alzheimer's Disease pipeline.
BIIBPositive Net Change RHHBYNegative Net Change PRTAPositive Net Change
biotechnology biotechs pharmaceuticals
Will Bristol Myers (BMY) Gain From New Drugs' Label Expansion?
by Zacks Equity Research
Label expansion of Bristol Myers' (BMY) new drugs should help it somewhat combat the decline in Revlimid sales due to generic competition.
BMYPositive Net Change NVOPositive Net Change MRKPositive Net Change LGNDPositive Net Change
biotechnology biotechs pharmaceuticals
3 Reasons to Buy Healthcare Stocks in the Current Market Environment
by Andrew Rocco
Healthcare stocks are currently providing investors with an attractive way to counterbalance a portfolio overexposed to tech. In general, healthcare stocks have lower betas, are more defensive, and have cleaner balance sheets.
AMDNegative Net Change UNHPositive Net Change PFEPositive Net Change MRKPositive Net Change ISRGNegative Net Change NVDANegative Net Change QQQNegative Net Change SMCINegative Net Change
biotechnology biotechs hospitals
Incyte (INCY) Down 9.6% so Far in 2023 on Recent Setbacks
by Zacks Equity Research
Incyte (INCY) shares are down 9.6% in the year so far on pipeline setbacks.
NVSPositive Net Change NVOPositive Net Change INCYPositive Net Change LGNDPositive Net Change
biotechnology biotechs pharmaceuticals
InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment
by Zacks Equity Research
InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patients.
CRSPNegative Net Change IFRXPositive Net Change KALAPositive Net Change KODNo Net Change
biotechnology medical vaccines
Biotech Stock Roundup: BLUE Announces Q4 Results, ONCT, ASND & RNA Fall on Updates
by Zacks Equity Research
Earnings and pipeline updates from bluebird bio (BLUE) and Avidity (RNA) are the key highlights for the biotech sector.
VRTXPositive Net Change RNAPositive Net Change ASNDNegative Net Change
biotechnology biotechs pharmaceuticals
CRISPR (CRSP) & Vertex Complete BLA Submission for Exa-Cel
by Zacks Equity Research
CRISPR (CRSP) and Vertex complete BLA submissions to the FDA for exa-cel for treating sickle cell disease and transfusion-dependent beta-thalassemia.
VRTXPositive Net Change CRSPNegative Net Change KALAPositive Net Change JSPRNo Net Change
biotechnology crispr gene-editing medical
Kodiak (KOD) Treats First Patient in Diabetic Macular Edema Study
by Zacks Equity Research
Kodiak (KOD) has its first patient in the early-stage study of KSI-501 for treating retinal diseases.
CRSPNegative Net Change KALAPositive Net Change KODNo Net Change JSPRNo Net Change
biotechnology medical
Oncternal (ONCT) Down on Restructuring Plan to Extend Runway
by Zacks Equity Research
Oncternal (ONCT) closes the development program for zilovertamab to extend its cash runway into 2025. Shares are down on the same.
AZNNegative Net Change NVOPositive Net Change LGNDPositive Net Change
biotechnology biotechs pharmaceuticals